ArticleTranslational cancer research2025
Machine learning-based prognosis prediction for serous ovarian cancer using the SEER database and data from a single center in China.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer, particularly serous ovarian cancer, is the leading cause of death among gynecological malignancies. Despite advances in treatment, prognosis remains poor due to the tumor's heterogeneity and the frequent late-stage diagnosis, making survival a critical concern for patients. However, there is a lack of accurate clinical prognostic models to guide treatment decisions. Therefore, this study aimed to develop and validate a robust prognostic model for serous ovarian cancer using machine learning. Methods: Data for this study were obtained from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2021) and Yancheng Dafeng People's Hospital (2012-2020). We used univariate and multivariate Cox regression analyses to identify independent risk factors and constructed a Light Gradient Boosting Machine (LightGBM) model with 10-fold cross-validation and hyperparameter tuning. The model's performance was evaluated using area under the receiver operating characteristic curve (ROC-AUC), feature importance rankings, and confusion matrices. Results: A total of 7,916 cases from the SEER database and 163 cases from Yancheng Dafeng People's Hospital were included in the analysis. The LightGBM model outperformed other machine learning models, with ROC-AUC values of 0.902 [95% confidence interval (CI): 0.881-0.923], 0.863 (95% CI: 0.841-0.886), 0.814 (95% CI: 0.794-0.835), and 0.816 (95% CI: 0.796-0.835) at 6, 12, 24, and 36 months, respectively, in the test set. Additionally, the model maintained robust performance in external validation, with ROC-AUC values of 0.821 (95% CI: 0.718-0.923), 0.785 (95% CI: 0.698-0.871), 0.745 (95% CI: 0.669-0.821), and 0.790 (95% CI: 0.722-0.858) at 6, 12, 24, and 36 months, respectively. We also identified surgery as the most significant predictor of survival, followed by chemotherapy, in ovarian cancer patients. Conclusions: We utilized the LightGBM model to predict survival in ovarian cancer patients, demonstrating excellent prognostic accuracy and high reproducibility. This model provides a valuable tool for guiding clinical decision-making and optimizing treatment strategies. Future research is needed to further validate its applicability across different populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.